A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. - Wikidata - wikimedia - TriplyDB

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

http://www.wikidata.org/entity/Q34768386

about

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers A review of the past, present, and future directions of neoplasia Neoplasia: Where We Have Been and Where We Are Going BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis Activation of the MEK-S6 pathway in high-grade ovarian cancers.Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity.Mechanisms of drug inhibition of signalling molecules.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies Integrating BRAF/MEK inhibitors into combination therapy for melanoma.Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.The future of targeted therapy approaches in melanoma.Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Neoplasia: An Anniversary of Progress.

P2860

Q26781362-18AE35B2-ECCA-4CC2-91AF-CBD48A27C154 Q28389391-EE539D62-A16D-44C6-A227-BAAE5E42C7AF Q28395095-E165D3F5-CC41-44EB-A748-33ECF5B53B84 Q28481390-6C491F75-7569-4B2F-B532-FFF9828708C5 Q33628125-9ACA80CE-6664-49C5-8BD2-B03C3F68AB7D Q33646519-F19DA022-8192-4DF6-A3B1-3F9EFD0E2F4F Q33906093-4F36530F-91C2-4D93-9C23-3A1EA8B4EC83 Q33971120-8472B909-91C6-466B-A8FC-0E79A2BA1EC1 Q34205937-0EB15651-23CF-4A8D-9D3E-358379D2CFCE Q34339010-47FE77ED-6DF3-4A0F-A8E0-52A79A30B740 Q35558850-86FCA539-EAF8-43CC-968D-74BFB0D52D94 Q36488752-3F26480A-915D-434F-BA59-538FA7E6070E Q36812355-4555FD01-7DC4-407A-B3A7-8F8EC8F0DAEB Q37135238-6C0FEF84-A346-40A5-9180-72B58ECB3E76 Q37285551-F17934DC-E731-4CC7-A8BB-C75B50746CCB Q37421431-6EC6B523-70AA-4F2E-81E2-E3F88FC524C6 Q37596249-8258F6D3-0864-4467-AEBE-8BD24FE25791 Q37977357-4E24C1F7-F41F-4928-866D-BAD1299E6EE2 Q38084846-194DD081-67CA-4662-848F-0D0970837154 Q38088812-7A4F1B73-1204-485A-BDB6-8E47E81B5927 Q38402255-7BDDAD4B-A748-4C9F-A708-825AC48B21D3 Q38635603-30FB078F-CFA9-4D45-8E3B-8D85D888077A Q39336729-FBF77812-F00A-479B-BAE9-91482E93DEB6 Q39409731-19A48CFC-D9D8-40D4-9188-C75CC9CDC093 Q39860040-03804922-1DA2-492E-B244-827BD2C0A5AB Q46932476-57DF4BAF-D23D-49FF-8786-10AE34988DB9

P2860

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

http://www.wikidata.org/entity/Q34768386

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@ast

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@en

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@nl

type

label

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@ast

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@en

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@nl

prefLabel

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@ast

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@en

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@nl

P1433

Q34768386-2EC38CC9-4BE9-4693-B23E-7CBE55E2792C

P1476

Q34768386-A14092B8-B9B0-4765-8B27-D4D26F2BE36B

P2093

Q34768386-0EDA476E-6860-4B66-BB39-27A548B54D7D

Q34768386-24ADBE3D-BF17-4C60-AFE1-47ABD39AFDD3

Q34768386-34C49E30-0B31-4D19-B056-7788F8F9320C

Q34768386-6F1C5372-F5DF-4072-BF08-681F07259FCD

Q34768386-D7C37E98-A31F-4251-9763-C55E578928FB

Q34768386-F84C6D73-4178-43B7-BA8A-CC91FCFF5E74

P2860

Q34768386-07899E66-C54C-4D4A-8B94-597926F02BB8

Q34768386-0AB9EF06-13FE-4D87-9364-CC85B47E4692

Q34768386-0C52E219-078A-4FEC-8F48-5D89BFAE3BD5

Q34768386-2DD091BB-E4B1-4B19-B962-BE4D6434AAD4

Q34768386-2EE8C7D4-D930-483E-A384-6E137F0B46D6

Q34768386-32F67BD2-4063-4FFA-AFE7-2AB699CDE7E2

Q34768386-3A52C74D-663F-4813-A3A0-9AB601EA9F09

Q34768386-4A15DBE9-5618-425C-8CA7-C3B09C3D383F

Q34768386-4C28FD2E-B0C4-47C3-B364-77F3C4BCE055

Q34768386-4F1C892F-D108-465E-A8A4-7BE9AF930958

P304

Q34768386-8436D5F5-B69D-4B9C-A36B-6712FA7AC1B0

P31

Q34768386-99645E28-C5C3-48D0-8F43-BA62B664FC2F

P356

Q34768386-7AD13602-5A26-4E1E-B0F4-C542B451CCB2

P433

Q34768386-78A993BB-4AD2-4E5D-926C-206EB9FA3F8E

P478

Q34768386-E4286877-B811-4EF4-A57B-4DCA146C68B8

P577

Q34768386-E9B0D6FA-D81F-4C7F-91A0-C523E9678172

P5875

Q34768386-E72254AF-B210-4DA0-8DFA-4A33D662C80A

P698

Q34768386-AB9C5B66-B089-40EF-8A56-939AD40821B5

P932

Q34768386-88124507-3CA3-499D-B99A-B7C21A22B931

P356

P1433

P1476

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

@en

P2093

Charles Omer

http://www.w3.org/2001/XMLSchema#string

Judith Sebolt-Leopold

http://www.w3.org/2001/XMLSchema#string

Keri Van Becelaere

http://www.w3.org/2001/XMLSchema#string

Ping Jiang

http://www.w3.org/2001/XMLSchema#string

Sally Przybranowski

http://www.w3.org/2001/XMLSchema#string

Yuli Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Mutations of the BRAF gene in human cancer

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

Mechanisms of regulating the Raf kinase family

Targeting RAS signalling pathways in cancer therapy

Regulation of the MAP kinase cascade

Transcriptional regulation by MAP kinases

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

ras oncogenes in human cancer: a review

G protein mechanisms: insights from structural analysis

P304

336-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.04532

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7776530

http://www.w3.org/2001/XMLSchema#string

P698

15967111

http://www.w3.org/2001/XMLSchema#string

P932

1501146

http://www.w3.org/2001/XMLSchema#string